[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-detail-350187-en":59,"doc-seo-350187-105":99},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":5,"data":60},{"doc_id":61,"user_id":62,"nickname":63,"user_avatar":64,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":66,"doc_content":67,"file_id":68,"file_url":69,"file_type":70,"file_size":71,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":72,"language":73,"language_code":74,"site_id":75,"html_lang":74,"table_of_contents":76,"faqs":77,"seo_title":78,"seo_description":66,"update_tm":79,"read_time":80,"preview_page_count":19,"preview_urls":81},350187,962085320529,"Sarah ","https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Tumor reactivity assessment using clonal expression reveals tumor reactive CD8+ T cell heterogeneity across solid tumors - Original Research","Tumor-infiltrating lymphocytes drive anti-tumor activity across immunotherapies, yet intratumoral CD8+ T-cell abundance alone cannot explain efficacy due to heterogeneous mixtures of tumor-reactive and bystander cells. A clonotype-level CD8+ tumor-reactive T cell classifier (TRACE) was trained on aggregated validated clonotypes with scRNA-seq to generalize across datasets. TRACE showed robust performance, experimentally confirmed reactivity via coculture, and scored higher exhausted CD8+ tumor-reactive frequencies in tumors across multiple atlases.","TYPE Original Research PUBLISHED 16 April 2026  \nDOI 10.3389/fimmu.2026.1815974  \nOPEN ACCESS  \nEDITED BY  \nGavin Bendle,  \nAstraZeneca, United Kingdom  \nREVIEWED BY  \nQi Zhao,  \nBioNTech, United States Frank Lowery,  \nNational Cancer Institute (NIH), United States  \n*CORRESPONDENCE  \nDipen Sangurdekar  \n [DSangurdekar@ksqtx.com](DSangurdekar@ksqtx.com)  \nRECEIVED 23 February 2026  \nREVISED 26 March 2026  \nACCEPTED 30 March 2026  \nPUBLISHED 16 April 2026  \nCITATION  \nMonteiro D, Denebeim J, Dodson AE, Yeri A, Ghose M, Travers M, Capobianco S, Calnan C, Martinez GJ, Yoon CH, Wong K, Benson MJ and Sangurdekar D (2026) Tumor reactivity assessment using clonal expression reveals tumor reactive CD8+ T cell heterogeneity across solid tumors. Front. Immunol. 17:1815974 .  \ndoi: 10.3389/fimmu.2026.1815974  \nCOPYRIGHT  \n© 2026 Monteiro, Denebeim, Dodson, Yeri, Ghose, Travers, Capobianco, Calnan, Martinez, Yoon, Wong, Benson and Sangurdekar. This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nTumor reactivity assessment using clonal expression reveals tumor reactive CD8 + T cell heterogeneity across solid tumors  \nDavid Monteiro 1, Jack Denebeim 1, Anne E. Dodson 1, Ashish Yeri 1, Mitali Ghose 1, Meghan Travers 1,  \nSophie Capobianco 1, Conor Calnan 1, Gustavo J. Martinez 1, Charles H. Yoon 2,3, Karrie Wong 1, Micah J. Benson 1 and Dipen Sangurdekar 1*  \n1 KSQ Therapeutics, Inc., Lexington, MA, United States, 2 Brigham and Women's Hospital, Boston, MA, United States, 3 Harvard Medical School, Boston, MA, United States  \nIntroduction: Tumor inﬁltrating lymphocytes (TIL) drive the anti-tumor activity of a broad class of immunotherapies. In situ TIL are composed of T cells that recognize tumor antigens (Tumor Reactive T cells, or TRTs) as well as bystander T cells with speciﬁcity for other antigens. TRT clonotypes are associated with a unique and tumor-driven exhausted transcriptional state, enabling single-cell RNA sequencing (sc RNA-seq)-based predictive models for TRTs using experimentally validated clone labels.  \nMethods: In this study, a clonotype-level CD8+ TRT classiﬁer (TRACE) was built using an aggregated dataset of validated tumor reactive clonotypes and associated scRNA-seq data from multiple publications that overcomes the limitations of training on a single dataset, donor, or indication. TRACE does not require dataset manipulation for training or prediction, enabling it to be easily applied to new test datasets as they emerge.  \nResults: TRACE exhibited robust performance on held-out TIL and PBMC clonesachieving a mean Matthews correlation coefﬁcient of 0 . 84 and F1-score of 0 .85-comparable to o r outperforming other TRT prediction methods. We experimentally conﬁrmed the reactivity of TRACE-identiﬁed TRT clones by coculturing ex vivo expanded TIL with an autologous melanoma tumor cell line. Finally, we applied TRACE to evaluate the frequency of TRTs across hundreds of patient samples from multiple tumor atlases spanning lung, colorectal, and pancreatic cancer. TRACE scores were observed to be signiﬁcantly higher in exhausted CD8+ T cells in tumors but not in exhausted cells in normal adjacent or non-cancer samples, suggesting speciﬁcity towards identifying tumor-antigen experienced T cells.  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nConclusion: TRACE is a tumor reactivity scoring algorithm released with open model weights that can be applied to tissue or blood single-cell RNAseq datasets. Its application should be of general interest for characterizing the fraction of TRTsin TIL and for establishing correla","cbCaihMXfxhBY8hX","https://ap.wps.com/l/cbCaihMXfxhBY8hX","pdf",4809937,14,"English","en",105,"# Introduction\n## Tumor-reactive versus bystander CD8+ T cells in the tumor microenvironment\n# Methods\n## TRACE clonotype-level CD8+ tumor-reactive T cell classifier\n# Results\n## Performance and experimental validation\n## Application across tumor atlases and patient samples\n# Conclusion","[{\"question\":\"What problem does TRACE address in tumor immunology research?\",\"answer\":\"It distinguishes tumor-reactive CD8+ T cells from bystander cells, where total CD8+ T-cell abundance is insufficient to explain immunotherapy efficacy.\"},{\"question\":\"How was TRACE developed to improve generalization across datasets?\",\"answer\":\"TRACE was built at the clonotype level using an aggregated dataset of experimentally validated tumor-reactive clonotypes and associated scRNA-seq data from multiple publications.\"},{\"question\":\"How was TRACE validated experimentally?\",\"answer\":\"Tumor reactivity of TRACE-identified TRT clonotypes was confirmed by coculturing ex vivo expanded TIL with an autologous melanoma tumor cell line.\"}]","Tumor reactivity assessment using clonal expression reveals tumor reactive CD8+ T cell heterogeneity across solid tumors - Original Research | PDF",1790087595,35,[82,86,90,95],{"page_no":8,"url":83,"width":84,"height":85},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/52bdf7cade26a6dd154138bd549b3235.webp",983,1389,{"page_no":14,"url":87,"width":88,"height":89},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bf12318b73a6419746d743af243343e3.webp",982,1388,{"page_no":91,"url":92,"width":93,"height":94},3,"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/79d664f7f115aaa19bea0e8785527233.webp",981,1386,{"page_no":19,"url":96,"width":97,"height":98},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/921c9183c72ba94a8c6274d2d7981d90.webp",980,1385,{"code":4,"msg":100,"data":101},"ok",{"site_id":75,"language":74,"slug":102,"title":65,"keywords":103,"description":66,"schema_data":104,"social_meta":157,"head_meta":159,"extra_data":161,"updated_unix":162},"tumor-reactivity-assessment-using-clonal-expression-reveals-tumor-reactive-cd8-t-cell-heterogeneity-across-solid-tumors-original-research","",{"@graph":105,"@context":156},[106,119,139],{"@type":107,"itemListElement":108},"BreadcrumbList",[109,113,115,117],{"item":110,"name":111,"@type":112,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":114,"name":9,"@type":112,"position":14},"https://docshare.wps.com/document/",{"item":116,"name":40,"@type":112,"position":91},"https://docshare.wps.com/document/research-report/",{"item":118,"name":65,"@type":112,"position":19},"https://docshare.wps.com/document/tumor-reactivity-assessment-using-clonal-expression-reveals-tumor-reactive-cd8-t-cell-heterogeneity-across-solid-tumors-original-research/350187/",{"url":118,"name":65,"@type":120,"image":121,"author":126,"headline":65,"publisher":128,"fileFormat":131,"inLanguage":74,"description":66,"dateModified":132,"datePublished":133,"encodingFormat":131,"isAccessibleForFree":134,"interactionStatistic":135},"DigitalDocument",{"url":122,"@type":123,"width":124,"height":125},"https://docshare.wps.com/thumbnails/tumor-reactivity-assessment-using-clonal-expression-reveals-tumor-reactive-cd8-t-cell-heterogeneity-across-solid-tumors-original-research/350187.png","ImageObject",300,407,{"name":63,"@type":127},"Person",{"url":110,"name":129,"@type":130},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":136,"interactionType":137,"userInteractionCount":52},"InteractionCounter",{"@type":138},"ViewAction",{"@type":140,"mainEntity":141},"FAQPage",[142,148,152],{"name":143,"@type":144,"acceptedAnswer":145},"What problem does TRACE address in tumor immunology research?","Question",{"text":146,"@type":147},"It distinguishes tumor-reactive CD8+ T cells from bystander cells, where total CD8+ T-cell abundance is insufficient to explain immunotherapy efficacy.","Answer",{"name":149,"@type":144,"acceptedAnswer":150},"How was TRACE developed to improve generalization across datasets?",{"text":151,"@type":147},"TRACE was built at the clonotype level using an aggregated dataset of experimentally validated tumor-reactive clonotypes and associated scRNA-seq data from multiple publications.",{"name":153,"@type":144,"acceptedAnswer":154},"How was TRACE validated experimentally?",{"text":155,"@type":147},"Tumor reactivity of TRACE-identified TRT clonotypes was confirmed by coculturing ex vivo expanded TIL with an autologous melanoma tumor cell line.","https://schema.org",{"og:url":118,"og:type":158,"og:title":65,"og:site_name":129,"og:description":66},"article",{"robots":160,"canonical":118},"index,follow",{"doc_id":61,"site_id":75},1790432791]